CRISPR and Gene Editing: A Game-changer in Drug Development


Cite item

Full Text

Abstract

CRISPR and gene editing technologies have emerged as transformative tools in medicine, offering unprecedented precision in targeting genetic disorders and revolutionizing drug development. This review explores the multifaceted impact of CRISPR across various medical domains, from hereditary diseases to infectious diseases and cancer. The potential of CRISPR in personalized medicine, therapeutic innovation, and pandemic prevention is highlighted, along with its role in reshaping traditional drug development processes. However, alongside its promise, ethical considerations loom large, particularly regarding germline editing and equitable access to treatments. The commercialization of CRISPR poses further challenges, raising questions about affordability and healthcare equity. Collaboration among scientists, policymakers, and the public is emphasized to navigate the ethical and societal implications of CRISPR responsibly. As the field advances, it is essential to ensure that the benefits of CRISPR are realized while addressing potential risks and maintaining a commitment to the well-being of future generations.

About the authors

Abhishek Verma

Department of Pharmaceutics, ISF College of Pharmacy,

Email: info@benthamscience.net

Tarun Sharma

Department of Pharmaceutics,, ISF College of Pharmacy

Email: info@benthamscience.net

Ankit Awasthi

Department of Pharmaceutics,, ISF College of Pharmacy

Author for correspondence.
Email: info@benthamscience.net

References

  1. Adli M. The CRISPR tool kit for genome editing and beyond. Nat Commun 2018; 9(1): 1911. doi: 10.1038/s41467-018-04252-2 PMID: 29765029
  2. Dimitri A, Herbst F, Fraietta JA. Engineering the next-generation of CAR T-cells with CRISPR-Cas9 gene editing. Mol Cancer 2022; 21(1): 78. doi: 10.1186/s12943-022-01559-z PMID: 35303871
  3. Bhattacharya S, Satpati P. Insights into the mechanism of CRISPR/Cas9-based genome editing from molecular dynamics simulations. ACS Omega 2023; 8(2): 1817-37. doi: 10.1021/acsomega.2c05583 PMID: 36687047
  4. Wang SW, Gao C, Zheng YM, et al. Current applications and future perspective of CRISPR/Cas9 gene editing in cancer. Mol Cancer 2022; 21(1): 57. doi: 10.1186/s12943-022-01518-8 PMID: 35189910
  5. Abdelnour SA, Xie L, Hassanin AA, Zuo E, Lu Y. The potential of CRISPR/Cas9 gene editing as a treatment strategy for inherited diseases. Front Cell Dev Biol 2021; 9: 699597. doi: 10.3389/fcell.2021.699597 PMID: 34977000
  6. Tsagkaraki E, Nicoloro SM, DeSouza T, et al. CRISPR-enhanced human adipocyte browning as cell therapy for metabolic disease. Nat Commun 2021; 12(1): 6931. doi: 10.1038/s41467-021-27190-y PMID: 34836963
  7. Binnie A, Fernandes E, Almeida-Lousada H, de Mello RA, Castelo-Branco P. CRISPR-based strategies in infectious disease diagnosis and therapy. Infection 2021; 49(3): 377-85. doi: 10.1007/s15010-020-01554-w PMID: 33393066
  8. Ding R, Long J, Yuan M, et al. CRISPR/Cas system: A potential technology for the prevention and control of COVID-19 and emerging infectious diseases. Front Cell Infect Microbiol 2021; 11: 639108. doi: 10.3389/fcimb.2021.639108 PMID: 33968799
  9. Chan YT, Lu Y, Wu J, et al. CRISPR-Cas9 library screening approach for anti-cancer drug discovery: Overview and perspectives. Theranostics 2022; 12(7): 3329-44. doi: 10.7150/thno.71144 PMID: 35547744
  10. Pascual-Gilabert M, Artero R, López-Castel A. The myotonic dystrophy type 1 drug development pipeline: 2022 edition. Drug Discov Today 2023; 28(3): 103489. doi: 10.1016/j.drudis.2023.103489 PMID: 36634841
  11. Gostimskaya I. CRISPR-Cas9: A history of its discovery and ethical considerations of its use in genome editing. Biochemistry 2022; 87(8): 777-88. doi: 10.1134/S0006297922080090 PMID: 36171658
  12. Brokowski C, Adli M. CRISPR ethics: Moral considerations for applications of a powerful tool. J Mol Biol 2019; 431(1): 88-101. doi: 10.1016/j.jmb.2018.05.044 PMID: 29885329
  13. Nxumalo Z, Takundwa MM, Thimiri Govinda Raj DB. Patents, ethics, biosafety and regulation using CRISPR technology. Prog Mol Biol Transl Sci 2021; 181: 345-65. doi: 10.1016/bs.pmbts.2021.01.023 PMID: 34127200
  14. Yunta ER, Vaschetto LM. Political, regulatory and ethical considerations of the CRISPR/Cas genome editing technology. CRISPR-/Cas9 based Genome Editing for Treating Genetic Disorders and Diseases. (1st Ed.). CRC Press 2022; pp. 71-84.
  15. van Dongen JE, Berendsen JTW, Steenbergen RDM, Wolthuis RMF, Eijkel JCT, Segerink LI. Point-of-care CRISPR/Cas nucleic acid detection: Recent advances, challenges and opportunities. Biosens Bioelectron 2020; 166: 112445. doi: 10.1016/j.bios.2020.112445 PMID: 32758911
  16. Hussen BM, Rasul MF, Abdullah SR, et al. Targeting miRNA by CRISPR/Cas in cancer: Advantages and challenges. Mil Med Res 2023; 10(1): 32. doi: 10.1186/s40779-023-00468-6 PMID: 37460924
  17. Uddin F, Rudin CM, Sen T. CRISPR gene therapy: Applications, limitations, and implications for the future. Front Oncol 2020; 10: 1387. doi: 10.3389/fonc.2020.01387 PMID: 32850447

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2024 Bentham Science Publishers